Table 2.
Univariable Analysis to Determine Risk of Severe Acute Kidney Injury and Mortality at 3-Month Follow-Up
| Severe AKI | Mortality after 3-month follow-up | |||
|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | |
| TDF exposure | 1.20 (1.02–1.40) | .013 | 1.00 (0.86–1.14) | .993 |
| HIV viral load suppressed | 1.10 (0.95–1.27) | .196 | 1.07 (0.90–1.26) | .763 |
| TB coinfection | 1.05 (0.90–1.22) | .516 | 1.21 (1.06–1.38) | .003 |
| Vomiting | 1.14 (1.00–1.30) | .046 | 1.14 (0.99–1.30) | .073 |
| Diarrhea | 1.20 (1.05–1.30) | .007 | 1.12 (0.96–1.30) | .164 |
| NSAID use | 1.06 (0.92–1.22) | .409 | 0.97 (0.83–1.14) | .706 |
| Severe AKI | N/A | N/A | 1.10 (0.97–1.26) | .144 |
95% CI, 95% confidence interval; AKI, acute kidney injury; OR, odds ratio.